Vasopressinase Activity: A Potential Early Biomarker for Detecting Cardiopulmonary Bypass-Associated Acute Kidney Injury?
06 September 2014
13 July 2015
14 September 2015 (online)
Background Acute kidney injury (AKI) is a common and serious complication of surgeries that include cardiopulmonary bypass (CPB). Currently, increases in serum creatinine levels are used to diagnose AKI, but this change may be slow to detect. Animal studies pertaining to renal hypoxia suggest a correlation between vasopressinase activity and AKI. The objective of this study is to determine if vasopressinase activity can be used as an early biomarker for renal hypoxia and CPB-associated AKI. This could potentially help improve the diagnosis and subsequent treatment of the condition.
Materials and Methods We conducted a single-center, prospective observational study which analyzed serum vasopressinase activity and creatinine levels at seven time points from 31 patients undergoing CPB. We also measured urine vasopressinase activity in 19 of the 31 patients at five of the time points.
Results Results show that serum and urine vasopressinase activity peak at the time of arrival to the ICU for patients undergoing CPB. This increase occurred earlier than the increase in creatinine, which generally occurred on postoperative day 2. In the five patients who were diagnosed with AKI, vasopressinase activity peaked 30 minutes into CPB while creatinine peaked on postoperative day 2.
Conclusion Our findings suggest that vasopressinase might be a potential early biomarker for AKI. Further studies with other AKI biomarkers are required to determine if the vasopressinase response can be directly attributed to the presence of AKI.
- 1 Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104 (4) 343-348
- 2 Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008; 73 (5) 538-546
- 3 Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2007; 2 (2) 356-365
- 4 Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90 (2) 133-138
- 5 Darby PJ, Kim N, Hare GM , et al. Anemia increases the risk of renal cortical and medullary hypoxia during cardiopulmonary bypass. Perfusion 2013; 28 (6) 504-511
- 6 Stafford-Smith M, Grocott HP. Renal medullary hypoxia during experimental cardiopulmonary bypass: a pilot study. Perfusion 2005; 20 (1) 53-58
- 7 Small CW, Watkins WB. A rapid and specific method for the determination of oxytocinase (cystine aminopeptidase) activity using continuous flow analysis and S-benzyl-L-cysteine-p-nitroanilide as substrate. Clin Biochem 1975; 8 (2) 124-132
- 8 Bagshaw SM, George C, Bellomo R ; ANZICS Database Management Committee. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23 (5) 1569-1574
- 9 Sampaio MC, Máximo CA, Montenegro CM , et al. Comparison of diagnostic criteria for acute kidney injury in cardiac surgery. Arq Bras Cardiol 2013; 101 (1) 18-25
- 10 Kobayashi H, Nomura S, Mitsui T , et al. Tissue distribution of placental leucine aminopeptidase/oxytocinase during mouse pregnancy. J Histochem Cytochem 2004; 52 (1) 113-121
- 11 Rogi T, Tsujimoto M, Nakazato H, Mizutani S, Tomoda Y. Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J Biol Chem 1996; 271 (1) 56-61
- 12 Masuda S, Hattori A, Matsumoto H , et al. Involvement of the V2 receptor in vasopressin-stimulated translocation of placental leucine aminopeptidase/oxytocinase in renal cells. Eur J Biochem 2003; 270 (9) 1988-1994
- 13 Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96 (9, Suppl): II-286-II-290
- 14 Levine FH, Philbin DM, Kono K , et al. Plasma vasopressin levels and urinary sodium excretion during cardiopulmonary bypass with and without pulsatile flow. Ann Thorac Surg 1981; 32 (1) 63-67
- 15 Lehot JJ, Villard J, Piriz H , et al. Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1992; 6 (2) 132-139
- 16 Philbin DM, Coggins CH, Wilson N, Sokoloski J. Antidiuretic hormone levels during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1977; 73 (1) 145-148
- 17 Villarejo AB, Segarra AB, Ramírez M , et al. Angiotensinase and vasopressinase activities in hypothalamus, plasma, and kidney after inhibition of angiotensin-converting enzyme: basis for a new working hypothesis. Horm Metab Res 2012; 44 (2) 152-154
- 18 Michalopoulos A, Stavridis G, Geroulanos S. Severe sepsis in cardiac surgical patients. Eur J Surg 1998; 164 (3) 217-222
- 19 Sharshar T, Carlier R, Blanchard A , et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30 (3) 497-500
- 20 Philbin DM, Coggins CH. Plasma vasopressin levels during cardiopulmonary bypass with and without profound haemodilution. Can Anaesth Soc J 1978; 25 (4) 282-285
- 21 Munshi R, Hsu C, Himmelfarb J. Advances in understanding ischemic acute kidney injury. BMC Med 2011; 9: 11
- 22 Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009; 20 (3) 672-679
- 23 Kim N, Voicu L, Hare GM , et al. Response of the renal inner medulla to hypoxia: possible defense mechanisms. Nephron, Physiol 2012; 121 (1–2) 1-7
- 24 Kumar AB, Suneja M. Cardiopulmonary bypass-associated acute kidney injury. Anesthesiology 2011; 114 (4) 964-970
- 25 Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004; 77 (3) 968-972
- 26 Garwood S, Swamidoss CP, Davis EA, Samson L, Hines RL. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth 2003; 17 (1) 17-21